High-Intensity Interval Training (HIIT) for Stage IV Cancer
Also known as: HIIT, High-intensity exercise, Sprint interval training
HIIT reduces cancer recurrence risk, improves treatment outcomes, and counteracts cancer-related fatigue through immune and metabolic effects.
Mechanism of Action
HIIT mobilizes NK cells (exercise-dependent 10-fold increase), enhances T cell function, reduces systemic inflammation, improves insulin sensitivity, and counteracts cancer-related fatigue and deconditioning. It also reduces cancer-related cognitive impairment.
General mechanism: High-intensity cardiovascular stress. BDNF/irisin release, PGC-1α activation, NK cell mobilization, insulin sensitization, angiogenesis.
Current Evidence
Meta-analyses show exercise reduces cancer recurrence by 20-40%. HIIT is more effective than moderate exercise for cardiopulmonary fitness and immune activation during treatment. Exercise oncology is now standard of care.
Clinical Status: Level 1 evidence for cancer outcomes. Exercise oncology integrated into treatment guidelines.
Safety Profile
Generally safe when appropriately prescribed. Cardiac screening recommended for sedentary individuals. Adapt to patient capacity. ALS: moderate intensity preferred.
Key Research Questions
- Does HIIT during chemotherapy improve treatment response through immune activation?
- Can exercise reduce cancer-related cognitive impairment?